Τίτλος:
Efficacy and safety of interferon-based therapy in the treatment of
adult thalassemic patients with chronic hepatitis C: a 12 years audit
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background. HCV infection and transfusional iron overload in Thalassemic
patients may result in liver disease. HCV treatment in Thalassemia has
raised safety concerns. Aim. Estimate effectiveness and tolerability of
interferon-based therapy in HCV-infected Thalassemic patients. Material
and methods. Over a 12-year period, consecutive patients with p
Thalassemia major (TM) and chronic hepatitis C received treatment. Liver
biopsy, HCV-RNA and genotyping were performed beforehand. Sustained
virological response (SVR) was defined as negative HCV-RNA 6 months
post-treatment. Forty eight patients (26 M-22 F, mean age 39.8) were
enrolled. Twenty nine patients were treated with conventional interferon
alpha (IFNa) for 48 weeks (group A). Nineteen patients (10 naive-9
previously IFNa experienced) received pegylated interferon (PEG-IFN)
(group B). Results. HCV-1 was found in 44%, HCV-2 in 14%, HCV-3 in
23% and HCV-4 in 19%. Group A: ten patients (38.5%) achieved SVR, 2
(7.5%) relapsed and 17 (54%) were non responders. Group B: five (28%)
achieved SVR, 8 (44%) relapsed and 6 (28%) never responded. High
HCV-RNA levels, genotype 1 and advanced liver fibrosis were
independently associated with no response. Four patients (3 treated with
IFNa, 1 with PEG-IFN) had to discontinue treatment due to complications.
Conclusions. The response rate of IFN monotherapy in multi-transfused,
HCV-infected Thalassemic patients is not inferior to that in
non-multi-transfused patients. IFNa administration is well-tolerated and
should be recommended as initial treatment schedule in this setting.
Συγγραφείς:
Vafiadis, Irene
Trilianos, Panagiotis
Vlachogiannakos, Jiannis
and Karagiorga, Markisia
Hatziliami, Antonia
Voskaridou, Ersi
and Ladas, Spiros D.
Περιοδικό:
Annals of Hepatology
Εκδότης:
ELSEVIER ESPANA SLU
Λέξεις-κλειδιά:
Anemia; HCV infection; Antiviral treatment; Pegylated interferon;
Thalassemia
DOI:
10.1016/S1665-2681(19)31336-5
